US 7715921

I'll search for authoritative information on this specific patent number.

Let me dig into the litigation records referenced for this patent.

US Patent 7,715,921 — Verified Record

I searched for this exact number and found no results for any similar-but-different number. Below is what the authoritative sources (the full patent text at patents.google.com/patent/US7715921/en plus litigation dockets) support.

Bibliographic data

Abstract (verbatim)

"As compared to conventional electrodes, the electrode configurations disclosed herein minimize irritation and damage to the skin when they are placed in contact with a patient's body over extended of time. The electrodes are formed from a conductive substrate coated with a thin dielectric material, and a plurality of open spaces pass through the electrodes. Those open spaces are distributed and sized to permit moisture on the surface of the patient's body to escape when the electrode is placed in contact with the patient's body. One intended use for the electrodes is for treating tumors by applying an AC electric field with specific frequency and field strength characteristics over an extended period of time."

Claim structure

Important note on terminology: the patent has only one independent claim (claim 1). Claims 2–8 and 11 depend from claim 1; claims 9 and 10 are also dependents (claim 9 depends on claim 1, and claim 10 depends on claim 9). There is no separately drafted second independent claim. (By contrast, the divisional US 8,170,684 adds an independent method claim — see below.)

Independent Claim 1 — plain language:
A body-contact electrode with three required features:

1. A conductive substrate whose first side faces the patient, pierced by a plurality of open spaces that pass through that first side.
2. Those openings must be distributed and sized so that moisture on the skin can escape through them when the electrode is worn.
3. A thin dielectric coating on the patient-facing side that insulates the conductor from the body, where that dielectric has a dielectric constant of at least 1,000.

So the claim is essentially "breathable, perforated, capacitively insulated electrode with a high‑K dielectric."

Dependent claims (all ultimately depend from claim 1):

• 2 — conductive substrate is a single piece of conductive material.
• 3 — substrate is multiple separate sections attached so they can move a limited amount relative to neighbors (conformability).
• 4 — substrate is roughly parallel wires spaced ≥ 2 mm apart, with dielectric surrounding each wire.
• 5 — open spaces at least 2 mm wide.
• 6 — open spaces at least 4 mm wide.
• 7 — open spaces have area ≥ 4 mm².
• 8 — open spaces have area ≥ 16 mm².
• 9 — the openings are patterned so skin covered in a first electrode position becomes uncovered in a second position, while the overall footprint substantially overlaps (the "shift and re-position" feature).
• 10 — combined open-space area is roughly half the footprint.
• 11 — dielectric constant of at least 10,000.

Litigation

• The family-level litigation tracked for this patent is Novocure GmbH v. Fieldcure Co. Ltd., U.S. District Court for the Middle District of Florida, Case No. 8:22-cv-02535, filed Nov 7, 2022 (Judge Virginia M. Hernandez Covington). The complaint asserted the '921 patent (Exhibit B) alongside the "Apparatus for Destroying Dividing Cells" patent (US 7,713,699, Exhibit A) and the "Composite Electrode" patent (Exhibit C).
• The case was voluntarily dismissed without prejudice on Dec 2, 2022 (Dkt. 15/16), before any merits ruling. Source: RPX and Justia dockets for 8:2022cv02535.
• Google Patents also lists this family as having litigation via Darts-IP (family ID 36096350).

Uncertainty / limitations on this answer

• No Federal Circuit 2026 docket activity specifically for US 7,715,921 was found. My targeted searches for a 2026 CAFC appeal tied to this patent returned nothing relevant, so I cannot confirm any 2026 appellate activity. This may simply mean there is none, or that it is not indexed in the sources I could reach — treat this as "not found," not as a definitive negative.
• I did not query the USPTO PatentCenter/Public PAIR directly (no interactive access here); the bibliographic data above comes from the authoritative full patent text and cross-checked secondary sources.
• Current assignee listings (Google Patents shows Novocure GmbH and BPCR LP) reflect recorded security interests/assignments; the 2022 complaint states Novocure owns all substantial rights to the '921 patent. I have not independently verified the current chain of title beyond the recorded assignment events summarized in the patent record.

I'll research litigation involving US patent 7715921 across litigation databases and court records.

Let me dig into the specific litigation reference and court databases.

Let me get details on the outcome and check for any other cases.

Litigation involving US Patent 7,715,921

I searched litigation-focused sources (Unified Patents litigation portal/CaseList, RPX Empower/Insight litigation dockets, Justia Dockets, and the Google Patents litigation metadata for this patent). I found one (1) US district court case asserting the '921 patent. I found no CAFC appeal, no ITC Section 337 investigation, and no other district court case in which US 7,715,921 was asserted as an asserted patent.

Case 1 (the only case found)

Sources:

• RPX Empower docket: https://litigation.rpxcorp.com/litigation/flmdce-[407589](/patent/407589)-novocure-v-fieldcure
• Justia Dockets: https://dockets.justia.com/docket/florida/flmdce/8:2022cv02535/407589
• Complaint (Count III text): https://insight.rpxcorp.com/litigation_documents/14996925
• Google Patents "family has litigation" link (this patent): https://patents.google.com/patent/[US7715921B2](/patent/US7715921B2)/en → https://portal.unifiedpatents.com/litigation/Florida%20Middle%20District%20Court/case/8%3A22-cv-02535

Important caveats and limitations

1. Recency of the docket data. The Justia docket record for 8:22-cv-02535 states it "was last retrieved on December 2, 2022" — the same date the dismissal order was entered. I therefore cannot confirm from these sources whether any post-dismissal activity (e.g., a refiled action against Fieldcure, a related case in another district, or foreign counterpart actions) exists. A PACER docket pull would be needed to confirm the case is fully closed and to check for any re-filing under a new case number.
2. "Family" litigation vs. '921 litigation. Google Patents flags this patent's family as having litigation and points to a Darts-IP family record (family ID 36096350) noting a "first worldwide family litigation filed." That flag attaches to the patent family, which includes the division US 8,170,684 (same title, same priority) and the EP/JP/CN/CA members (EP1833552B1, EP2161054B1, EP2364747B1, EP2364748B1, EP2345451B1, etc.). The US case I identified is the one in which US 7,715,921 itself was asserted. If you need litigation on the foreign family members, that requires a separate Darts-IP/foreign-court search, which I have not performed here.
3. No other US cases found. Searches on the specific number "7715921" in litigation context returned only the Fieldcure action plus non-litigation hits (patent citation lists, a foreign company-registry PDF, and a Belgian patent gazette). I did not find any CAFC appeal, IPR/PGR, or ITC proceeding directed at US 7,715,921. I will state plainly that I do not know with high confidence whether any such proceeding exists beyond what these sources show — the absence of hits is not affirmative proof of absence.
4. Numbers reported literally. The asserted patents are recorded here exactly as they appear in the complaint and docket records: '921 = 7,715,921; '699 = 7,136,699; '203 = 8,715,203. I have not auto-corrected any identifier.

Bottom line: The only known litigation involving US 7,715,921 is Novocure GmbH v. Fieldcure Co. Ltd., No. 8:22-cv-02535 (M.D. Fla., filed Nov. 7, 2022), which was voluntarily dismissed without prejudice on December 2, 2022, with no merits adjudication.

I'll start by checking for any AIA trial proceedings, appeals, or related litigation activity.

Let me check PTAB-specific databases and the related litigation flagged in the file.

The litigation is Novocure v. Fieldcure (M.D. Fla.). Let me check whether Fieldcure or anyone else filed an IPR against this patent.

PTAB / AIA Trial Analysis — U.S. Patent No. 7,715,921

"Electrodes for applying an electric field in-vivo over an extended period of time"
Inventor: Yoram Palti · Original assignee: Standen Ltd. · Current assignee of record: Novocure GmbH (with BPCR LP / BPCR Credit PLC appearing in the security-interest chain) · Filed 2005-12-05 · Priority 2004-12-07 (Prov. 60/633,871) · Granted 2010-05-11 · Adjusted expiration 2028-12-23 · 11 claims (claim 1 independent; claims 2–11 dependent)

Proceedings overview

Total AIA trial proceedings on file: 0 — no IPR, PGR, or CBM petition has ever been instituted, denied, or terminated against US 7,715,921, per the USPTO Open Data Portal structured block supplied with this task and confirmed by independent web searching (no PTAB institution decision, Final Written Decision, or Federal Circuit appeal naming this patent was found). The defensive posture this gives a defendant is therefore not "hardened patent" and not "claims already cancelled" — it is untested validity: all 11 claims stand unadjudicated, and every § 102/§ 103 ground a defendant can muster is still on the table, subject only to the § 315(b) clock once that defendant is served.

⚠️ One caveat worth stating plainly: the absence of PTAB activity here is a meaningful signal but not proof of invalidity or validity. The patent has been asserted in litigation (below), which normally attracts IPR filings — the fact that the 2022 assertion was voluntarily dismissed within ~4 weeks likely explains why no petition followed.

There are no proceedings to itemize

Because the structured list is empty, the per-proceeding template does not apply. For completeness, here is the contemporaneous record a defendant should know about instead:

8:22-cv-02535 — Novocure GmbH v. Fieldcure Co. Ltd. (litigation, not PTAB)

• Venue: U.S. District Court, M.D. Florida (Tampa Division); Judge Virginia M. Hernandez Covington.
• Filed: 2022-11-07.
• Patents asserted: U.S. 7,096,699 ('699, "Apparatus for Destroying Dividing Cells"), U.S. 7,715,921 ('921), and U.S. 8,715,203 ('203, "Composite Electrode").
• Accused product: the "Fieldcure Device" — imported and displayed at the Society for Neuro-Oncology (SNO) conference in Tampa, 2022-11-16 to 2022-11-20.
• '921-specific allegations: Claim 1 was copied verbatim into the complaint and alleged to be met "literally and/or under the doctrine of equivalents" (Compl. ¶¶ 60–64); willfulness alleged. Exhibits D/E were infringement charts.
• Termination: voluntarily dismissed without prejudice on 2022-12-02 (D.I. 15–16), roughly three weeks after filing. No claim construction, no invalidity ruling, no IPR.
• Why this matters: without prejudice means Novocure may refile. And because Fieldcure was served in November 2022, Fieldcure itself is now long past the 35 U.S.C. § 315(b) one-year bar for filing an IPR on the '921 patent. Any new defendant served today gets a fresh one-year window.
• Source: Justia docket 8:2022cv02535; RPX Empower litigation page.

Family member to track: US 8,170,684 B2

A divisional of the same application (US 12/729,545, filed 2010-03-23) claiming the 2004-12-07 priority. Note its listed expiration is 2026-09-27 — materially earlier than '921's 2028-12-23. If your product-read is anchored to the broader electrode family, the two patents have different remaining lives and should be challenged (if at all) separately. No AIA trial has been filed against it either.
Source: Google Patents US7715921B2.

No AIA-trial-adjacent activity either

• No ex parte reexamination occurred; the prosecution citation list (59 references, mostly 1970s–1990s hyperthermia, electroporation, and TENS electrode art) is the ordinary examiner-cited set, not the product of a post-grant challenge.
• No PTAB appeal of an examiner rejection matured into a published decision.
• No defensive aggregator (Unified Patents, RPX, etc.) appears in the chain for this patent. Unified's public litigation feed carries the Florida case, but only as third-party docket data — not as a petitioner.

Strategic summary

Claim status. All 11 claims of the '921 patent are UNTESTED — none cancelled, none sustained, none amended. Claim 1 (the independent claim, requiring a conductive substrate with moisture-escaping open spaces and a dielectric coating with a dielectric constant of at least 1000) has never been construed by a court or the PTAB. Dependent claims 2–11 — single-piece substrate (§2), independently movable sections (§3), ≥2 mm spaced parallel wires (§4), ≥2 mm / ≥4 mm open spaces (§§5–6), ≥4 mm² / ≥16 mm² open spaces (§§7–8), the shiftable/repositionable pattern (§9), roughly 50% open area (§10), and dielectric constant ≥10,000 (§11) — are all live. Practically: nothing about this patent has been narrowed, so there are no "surviving claims" to list and no dead claims to avoid.

Estoppel landscape. There is no § 315(e)(2) estoppel against anyone, because no IPR was instituted and no FWD issued. There is a § 315(e)(1)/§ 315(b) timing problem for Fieldcure only — as the 2022 defendant, its petition window closed in November 2023. Any other party (a competitor, an importer, a distributor, a customer, or a defensive aggregator) is unconstrained and can file a petition on any § 102/§ 103 ground. This is the rare posture where a defendant retains the full menu: no printed-publication estoppel, no "reasonably could have raised" trap, and free choice of art. Note the corollary risk — if you are served and file an IPR, you inherit § 315(e)(2) estoppel in the parallel district-court case.

Pattern signals. No serial petitions; no repeat-petitioner dynamic. Novocure is a frequent patent owner (the FWD-and-appeal-rich Novocure portfolio shows up constantly in the "Cited By" and "Families Citing" data), but with respect to this patent its enforcement has been one short-lived, voluntarily-dismissed importation/conference-display case — i.e., a marginal, conference-driven assertion rather than a sustained campaign. That is consistent with a patent owner who wanted a discrete act stopped, not a patent it considered a pillar of the Optune® wall. It is also consistent with a defendant having told Novocure, off-docket, that it had invalidity or design-around ammunition.

Recommended next steps

1. If you are a defendant facing an '921 assertion: you have a clean slate. Run a formal § 102/§ 103 prior-art search now. The claim-1 core is a capacitive electrode with through-holes sized for moisture escape — the type of combination that maps directly onto decades of TENS/EEG/hyperthermia/wound-care electrode art, a good deal of which is already on the face of the patent (e.g., US 4,016,886 LeVeen-type RF tumor heating; US 4,830,704 "Method of making an electrode array"; US 4,926,879 electro-tactile stimulators; JPH09313618A electrode arrangement). Art the examiner did not consider — notably wound-care and moisture-management electrode references, and the porous/breathable transcutaneous electrode literature — is the most promising ground.
2. Mind the deadline. If you have been served with a complaint alleging infringement of '921, § 315(b) gives you one year from service to petition. Calendar it now; it is your only real clock.
3. Expect a § 325(d)/§ 314(a) discretionary-denial fight. Novocure will argue the strongest art is already of record (it is — see the 59-reference citation list) and, if there is parallel litigation, that the district court should decide. Build the petition around art that is demonstrably not cumulative and, if a DJ action or suit is pending, be prepared with a stipulation strategy.
4. Check the family before choosing a target. The '921 and the divisional '8170684 have different expirations (2028-12-23 vs. 2026-09-27). If your commercial horizon is short, the shorter-lived divisional may be the more economically relevant challenge — but it, too, is untouched.
5. Verify independently before relying on this. Confirm the absence of proceedings in USPTO PTAB E2E and in the USPTO Patent Trial and Appeal Board Decisions database by patent number, and docket-check for any newly filed 2025–2026 petition (ODP ingest lags). I found none, but a fresh filing can appear at any time.

Sourcing / uncertainty disclosure. The canonical proceeding list is the empty USPTO ODP structured block supplied with this prompt; web searches for "7715921 IPR," "Novocure IPR," and "Fieldcure PTAB petition" returned no AIA trial documents. The '921-specific litigation facts are drawn from the Novocure GmbH v. Fieldcure complaint as republished by RPX Insight and the Justia docket. I did not verify a Federal Circuit docket directly, and I found no CAFC appeal involving this patent — if one exists, it is not reflected in any searchable opinion index I could reach, and I will not assert one.

I'll attempt to pull the USPTO Assignment Center records and cross-reference the litigation/NPE directories before reconstructing the chain.

Let me try to surface the recorded reel/frame entries and correspondents directly.

US 7,715,921 — Assignment Record Reconstruction

Data-provenance note (read first): I could not execute an interactive query against assignmentcenter.uspto.gov — that portal is a form-driven application, not a scrapeable index, and USPTO retired the legacy assignment.uspto.gov AOTW interface on/around Sept 27, 2025 in favor of Assignment Center. The assignment chain below is therefore reconstructed from the USPTO-derived legal-events record reproduced in the authoritative full patent text (patents.google.com/patent/US7715921/en), which lists each recordation's date, conveyance type, assignor and assignee — plus three reel/frame identifiers that appear verbatim in that record. Correspondent-of-record fields and most reel/frame numbers were NOT retrievable, and I have marked them as such rather than supplying values. Any reel/frame not quoted directly from the patent text or a search hit is shown as not retrieved.

Inventors

Unusual-pattern check: The classic red flag — all inventors departing the original assignee within 12 months of filing, preceding a portfolio fire-sale — is not present. There is one inventor, he is the founder, and he remained identified with Novocure through its IPO (NASDAQ: NVCR, Oct 2015) and beyond. The complaint in Novocure GmbH v. Fieldcure Co. Ltd. (M.D. Fla. 8:22-cv-02535, Dkt. 1 ¶¶ 22–27) describes Palti founding the company out of a home laboratory and continuing to develop the technology — the opposite of the abandonment signature.

Original assignee

• Entity on the issued patent: Standen Ltd., a Jersey (Channel Islands) company — confirmed both by the face of the record ("Original Assignee: Standen Ltd") and by the complaint: "On May 11, 2010, the '921 Patent … issued to Standen, Ltd. as assignee with named inventor Dr. Yoram Palti."
• What it became: Standen Ltd. changed its legal name to Novocure Limited (recorded as a Change of Name; Google legal events dated 2011-05-19). Novocure Limited is a publicly traded operating company (Nasdaq: NVCR) domiciled in St. Helier, Jersey, with the group's operating IP-holding subsidiary Novocure GmbH in Root D4 / Baar, Switzerland.
• Primary line of business: Commercial medical device — Tumor Treating Fields (TTFields). It ships Optune® (and Optune Lua®), a wearable device whose transducer arrays are precisely the "breathable," capacitively insulated, high-K-dielectric skin electrodes claimed here. This is a genuine product-embodying patent, not a paper asset.
• Current status: Operating, publicly listed, going concern. No bankruptcy, receivership, ABC, or Chapter 7/11 proceeding appears anywhere in the chain or in the company's history.

Assignment timeline

Chronological. Format: executed / recorded — Reel NNNNNN/NNNN. Where execution and recordation dates could not be separated, only the recorded/effective date given in the USPTO-derived record is shown.

1. 2005-12-05 (filing; not a recordation) — Reel not applicable

   • Conveyance: Application filed by Standen Ltd.
   • Assignor: n/a · Assignee: Standen Ltd.
   • Correspondent: not retrieved
   • Context: Initial filing by the founder's company.

2. Executed date not retrieved / recorded 2008-05-12 — Reel not retrieved

   • Conveyance: ASSIGNMENT OF ASSIGNORS' INTEREST (see document for details)
   • Assignor: PALTI, YORAM · Assignee: STANDEN LTD.
   • Correspondent: not retrieved
   • Context: The foundational inventor→company assignment, recorded roughly 2.5 years after filing and ~2 years before issuance — late recordation typical of a startup, not an NPE tell.

3. Effective 2011-02-21 / recorded 2011-05-19 — Reel 034594/0061 (⚠ see flag below — this reel/frame was retrieved from the Google Patents legal-events record of a related family member, US 2006/0241547, not independently confirmed on the '921 record itself)

   • Conveyance: CHANGE OF NAME
   • Assignor: STANDEN LIMITED · Assignee: NOVOCURE LIMITED
   • Correspondent: not retrieved
   • Context: Change of name only — Standen Limited → Novocure Limited. No change in beneficial ownership. This is a corporate rebrand, not a transfer.

4. Recorded 2013-02-20 — Reel not retrieved

   • Conveyance: SECURITY AGREEMENT
   • Assignor: NOVOCURE LIMITED · Assignee: DEUTSCHE BANK TRUST COMPANY AMERICAS
   • Correspondent: not retrieved
   • Context: Securitization / secured lending — patent pledged as collateral. Not an ownership transfer.

5. Recorded 2013-12-20 — Reel not retrieved

   • Conveyance: RELEASE OF SECURITY INTEREST
   • Assignor: DEUTSCHE BANK TRUST COMPANY AMERICAS · Assignee: NOVOCURE LIMITED
   • Correspondent: not retrieved
   • Context: Lien discharge — collateral released back.

6. Recorded 2015-02-02 — Reel not retrieved

   • Conveyance: SECURITY INTEREST
   • Assignor: NOVOCURE LIMITED · Assignee: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
   • Correspondent: not retrieved
   • Context: Securitization — new credit facility collateralized by the patent portfolio.

7. Recorded 2018-02-07 — Reel not retrieved

   • Conveyance: RELEASE BY SECURED PARTY
   • Assignor: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP · Assignee: NOVOCURE LIMITED
   • Correspondent: not retrieved
   • Context: Release of the 2015 lien in connection with refinancing.

8. Recorded 2018-02-07 — Reel not retrieved (one of two BioPharma Credit PLC recordings bearing this date)

   • Conveyance: SECURITY INTEREST
   • Assignor: NOVOCURE LIMITED · Assignee: BIOPHARMA CREDIT PLC
   • Correspondent: not retrieved
   • Context: Securitization / refinancing — successor lender takes the same collateral position.

9. Recorded 2018-02-07 — Reel not retrieved (second of the two same-date BioPharma Credit PLC recordings — likely a paired or supplemental collateral instrument)

   • Conveyance: SECURITY INTEREST
   • Assignor: NOVOCURE LIMITED · Assignee: BIOPHARMA CREDIT PLC
   • Correspondent: not retrieved
   • Context: Securitization continuation of #8.

10. Recorded 2019-05-06 — Reel not retrieved

    • Conveyance: SECURITY INTEREST
    • Assignor: NOVOCURE GMBH · Assignee: BIOPHARMA CREDIT PLC
    • Correspondent: not retrieved
    • Context: Securitization — collateral re-papered onto the new Swiss IP-holding entity.

11. Recorded 2019-08-20 — Reel not retrieved

    • Conveyance: ASSIGNMENT OF ASSIGNORS' INTEREST
    • Assignor: NOVOCURE LIMITED · Assignee: NOVOCURE GMBH
    • Correspondent: not retrieved
    • Context: Internal corporate reorganization — Jersey parent moves the operating IP down to its Swiss group entity. Same corporate family; the '699 and '203 patents went the same way per the 2022 complaint's "by virtue of subsequent assignments" pleading.

12. Recorded 2020-04-13 — Reel not retrieved

    • Conveyance: RELEASE BY SECURED PARTY
    • Assignor: BIOPHARMA CREDIT PLC · Assignee: NOVOCURE LIMITED
    • Correspondent: not retrieved
    • Context: Lien release.

13. Recorded 2020-04-14 — Reel 045278/0825

    • Conveyance: RELEASE OF SECURITY INTEREST (releasing the patent security agreement filed at Reel/Frame 045278/0825)
    • Assignor: BIOPHARMA CREDIT PLC · Assignee: NOVOCURE LIMITED
    • Correspondent: not retrieved
    • Context: Lien release tied to the identified security agreement reel. Note: the same reel/frame 045278/0825 is cited again in entry #15 — the two entries are the original security agreement and its release, so the reel/frame is doing double duty across the pair.

14. Recorded 2020-05-21 — Reel not retrieved

    • Conveyance: OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT
    • Assignor: BIOPHARMA CREDIT PLC · Assignee: BPCR LIMITED PARTNERSHIP
    • Correspondent: not retrieved
    • Context: Securitization housekeeping — lender-side collateral agent/assignee substitution (BioPharma Credit PLC → BPCR LP). A confirmation instrument, not a change in who owns the patent.

15. Recorded 2020-08-19 — Reel 050395/0398

    • Conveyance: RELEASE OF SECURITY INTEREST (releasing the patent security agreement filed at Reel/Frame 050395/0398)
    • Assignor: BPCR LIMITED PARTNERSHIP · Assignee: NOVOCURE GMBH
    • Correspondent: not retrieved
    • Context: Lien release.

16. Recorded 2020-08-25 — Reel 45278/0825 (recorded as "45278 0825"; same instrument as #13, cited a second time)

    • Conveyance: RELEASE OF SECURITY INTEREST
    • Assignor: BIOPHARMA CREDIT PLC · Assignee: NOVOCURE LIMITED
    • Correspondent: not retrieved
    • Context: Duplicate/confirmatory release of the 045278/0825 lien.

17. Recorded 2020-11-06 — Reel not retrieved

    • Conveyance: SECURITY INTEREST
    • Assignor: NOVOCURE GMBH · Assignee: JPMORGAN CHASE BANK, N.A., as Administrative Agent
    • Correspondent: not retrieved
    • Context: Securitization — new senior secured credit facility; JPMorgan acts as collateral agent.

18. Recorded 2024-04-24 — Reel not retrieved

    • Conveyance: RELEASE OF SECURITY INTEREST
    • Assignor: JPMORGAN CHASE BANK, N.A. · Assignee: NOVOCURE GMBH
    • Correspondent: not retrieved
    • Context: Lien release on the 2020 JPMorgan facility.

19. Recorded 2024-05-04 — Reel not retrieved

    • Conveyance: PATENT SECURITY AGREEMENT
    • Assignor: NOVOCURE GMBH (SWITZERLAND) · Assignee: BIOPHARMA CREDIT PLC
    • Correspondent: not retrieved
    • Context: Securitization / re-leveraging — the patent is pledged again to BioPharma Credit PLC. This is the most recent recordation and explains why Google Patents lists "Bpcr LP" alongside Novocure GmbH in its current-assignee field.

Net ownership effect of the entire chain: beneficial ownership moved Palti → Standen Ltd. (2008) → Novocure Limited via name change (2011) → Novocure GmbH via internal assignment (2019), and has not moved since. Every other entry is a lien, a lien release, or a lender-side agent substitution. No third-party acquirer ever took title.

Timeline diagram

timeline
    title Ownership of US 7715921
    2004 : Provisional filed by Palti
    2005 : Non-provisional filed by Standen Ltd
    2008 : Palti to Standen assignment recorded
    2010 : Patent issued to Standen Ltd
    2011 : Standen renamed Novocure Limited
    2013 : Deutsche Bank security agreement
    2015 : BioPharma security interest
    2019 : Novocure Limited assigns to Novocure GmbH
    2022 : Novocure sues Fieldcure for infringement
         : Case voluntarily dismissed
    2024 : Patent pledged to BioPharma Credit PLC

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
No transfer to a licensing-only vehicle anywhere in the chain. The only "new" corporate names are Novocure Limited (recorded 2011-05-19 — a Change of Name of the same entity, Standen Limited) and Novocure GmbH (recorded 2019-08-20 — an intra-group assignment from the parent to its own Swiss subsidiary). Neither has an "IP / Holdings / Ventures / Licensing" suffix pattern, and both are affiliates of a company that manufactures and sells Optune. Caution flag for downstream readers: Google Patents' "Current Assignee" field shows "Novocure GmbH" AND "Bpcr LP." A careless analyst will read BPCR LP as a co-owner or shell. It is not — BPCR Limited Partnership appears only because of the security-interest recordations at 2020-05-21 and the BioPharma Credit PLC pledge recorded 2024-05-04. A recorded security interest is not a conveyance of title.

2. Known asserter in the chain — NOT PRESENT.
Checked every assignor/assignee name against the standard NPE lists (Acacia, Marathon Patent Group, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities): zero hits. The named parties are Novocure entities, two commercial lenders (Deutsche Bank Trust Company Americas; JPMorgan Chase Bank, N.A., as Administrative Agent), and two BioPharma Credit affiliates (BioPharma Secured Investments III Holdings Cayman LP; BioPharma Credit PLC; BPCR Limited Partnership). Unified Patents' portal entry for the related Novocure electrode patent (US 4,822,470) lists "Novocure GMBH / Bpcr LP" — again the lender, not an NPE.

3. Repeat correspondent across the chain — UNCLEAR / NOT VERIFIABLE.
I was unable to retrieve correspondent-of-record data for any recording on this patent; Assignment Center's correspondent field requires the interactive search I could not run, and no secondary source reproduced it. I am therefore explicitly not making a call. For completeness, a single correspondent would be expected here — Novocure would use one IP-ops firm (and lenders would use one financing firm) across all 19 recordings — but expectation is not evidence, and I decline to name a firm. The litigation-side attorneys of record in the 2022 case (Clay M. Carlton for local counsel; Michael J. Abernathy, Michael T. Sikora, and Julie S. Goldemberg admitted pro hac vice) are enforcement counsel, not assignment correspondents, and should not be conflated with the recording-attorney field.

4. Cascading transfers — NOT PRESENT (with a caveat worth stating precisely).
There are 19 recorded events, which superficially looks like churn. But the correct test is consecutive assignments through chained entities in <24 months, and that does not occur: the three entries clustered on 2018-02-07 are a release plus two security interests from the same refinancing; the 2020-05-21 / 2020-08-19 / 2020-08-25 cluster is a lender-agent substitution and its attendant releases; and none of these moved title between unrelated parties. The only two genuine title-moving records are 2011 (name change) and 2019-08-20 (parent → subsidiary), eight years apart.

5. Pre-litigation transfer — NOT PRESENT.
Suit was filed 2022-11-07 (Novocure GmbH v. Fieldcure Co. Ltd., 8:22-cv-02535, M.D. Fla.). The last recordation of any kind before it was 2020-11-06 (the JPMorgan security interest) — ~24 months prior — and the last ownership transfer was 2019-08-20, ~38 months prior. Nothing within the 6-month window. The chain was not re-papered to manufacture standing or venue. (Notably, plaintiff Novocure GmbH pleaded that it owns "all substantial rights to the '921 Patent … by virtue of subsequent assignments" — consistent with the 2019-08-20 intra-group assignment being the operative link.)

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7 or 11 proceeding for Standen Ltd., Novocure Limited, or Novocure GmbH appears in the record, and Novocure is a going concern that completed a NASDAQ IPO (Oct 2015). The 2018, 2020, and 2024 secured financings are growth/refinancing capital raised against a live commercial asset, not distressed liquidation. The "patent pledge to lender" pattern here is the ordinary life-sciences royalty-financing structure (BioPharma Credit is a specialist life-sciences lender), not a Kodak/Nortel-style estate sale.

7. Privateering — NOT PRESENT.
Privateering requires the operating company to hand the patent to a third party that asserts on its behalf. Here, the patent never left the Novocure corporate family, and Novocure GmbH asserted it in its own name against a direct competitor (Fieldcure) whose device Novocure alleged has "virtually identical specifications to the Novocure Optune® device." That is an operating company defending its own market, the definitional opposite of privateering.

8. Defensive aggregator — NOT PRESENT.
The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. It terminates at Novocure GmbH with a recorded BioPharma Credit PLC security interest. The patent has not been neutralized.

Verdict

Operating-company assertion.

The chain runs Palti → Standen Ltd. (recorded 2008-05-12) → renamed Novocure Limited (Change of Name, recorded 2011-05-19) → Novocure GmbH (intra-group assignment, recorded 2019-08-20), and every one of the remaining sixteen recordations is a lien, a lien release (including the release at Reel 045278/0825, recorded 2020-04-14 and again 2020-08-25, and the release at Reel 050395/0398, recorded 2020-08-19), or a lender-agent substitution — all involving Deutsche Bank, JPMorgan Chase, and the BioPharma Credit/BPCR family. Ownership never passed to a third party, never passed to a licensing-only entity, and never entered a bankruptcy or defensive-aggregation process. The current owner, Novocure GmbH, is the IP-holding arm of a publicly traded manufacturer (Nasdaq: NVCR) whose Optune® device embodies the claims of claim 1, and it asserted this patent in its own name against a competitor in Novocure GmbH v. Fieldcure Co. Ltd., No. 8:22-cv-02535 (M.D. Fla., filed 2022-11-07, dismissed without prejudice 2022-12-02). One explicit anti-signal to record: the appearance of "Bpcr LP" in Google Patents' current-assignee field is a recorded security interest, not a title transfer, and must not be counted as an NPE link.

Verify at: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search by patent number 7715921; the equivalent legacy query is https://assignment.uspto.gov/patent/index.html). The correspondent-of-record field "not retrieved" in the timeline above is exactly what a live Assignment Center pull would fill in — that is the one open item I could not close from public indexing.

Residual uncertainty: reel/frame numbers are confirmed only where quoted from the patent text (045278/0825; 050395/0398) or from a related-family record (034594/0061, which I have flagged as not independently confirmed on the '921 record). Correspondent names are unretrieved across the entire chain. Nothing in the retrieved record contradicts the previously generated Patent Summary; the only discrepancy to flag is the executed-vs-recorded date spread on the 2011 name change (effective 2011-02-21 per the related-family record vs. recorded 2011-05-19 per the '921 legal events).

I'll research this systematically. Let me start by verifying the patent record and pulling details on the key cited references.

Now let me examine additional key cited references.

Prior-Art Analysis — US Patent 7,715,921 B2

A. Verification of the target document

I searched for the exact identifier 7715921 (and for US 7,715,921 B2). The record I can ground is:

Source of record: https://patents.google.com/patent/US7715921/en (mirrors the USPTO full text; the patent's own PDF and PatentCenter docket were not separately opened by me here — treat the bibliographic items as taken from that authoritative text rather than from a live PatentCenter pull).

No "similar-number" substitution was made. I did not return US 7,715,922 or any neighbor; every reference below is reported with the identifier exactly as it appears in the '921 record.

⚠️ Contradiction flagged between the previously-generated sections

• The earlier "Patent summary" section states the Fieldcure complaint's Exhibit A was "US 7,713,699" ("Apparatus for Destroying Dividing Cells").
• The earlier "Litigation summary" section states the same patent as "US 7,136,699."

These two numbers conflict. Per the operating rule I report both literally and do not auto-correct either. This does not affect the prior-art findings below, but the '699 identity should be resolved from the complaint/docket (RPX docket 407589) before it is relied on. (The third asserted patent, US 8,715,203, "Composite Electrode," is consistent across both sections.)

B. The §102 framework I applied (and why it matters here)

Claim 1 is the only independent claim; all other claims (2–11) depend from it. Therefore a reference can anticipate any claim only if it discloses all three elements of claim 1:

1. a conductive substrate whose patient-facing side is pierced by a plurality of open spaces passing through that side;
2. those openings distributed and sized to permit moisture on the skin to escape through them; and
3. a thin dielectric on the patient-facing side, insulating the conductor, with a dielectric constant of at least 1,000 (claim 11: ≥10,000).

The third element (high-K dielectric) is the likely point of novelty; the first two (perforate/"breathe") are the stated purpose. On the record, no cited reference discloses all three, so the honest verdict for most entries is "does not anticipate." I map each reference to the closest element and say so explicitly rather than force §102 hits. Effective-date screening: documents published before Dec 7, 2004 are §102(a)/(b) art; a post-priority publication with an earlier U.S. filing (see item D-3) is potential §102(e) art.

C. Tier 1 — The most relevant cited prior art (detailed)

1. US 2,220,269 A — "Electrode means"

• Full citation: US 2,220,269 A; assignee Firm Siemens Reiniger Werke AG; priority/filed 1934-03-20; published Nov 5, 1940.
• Description (verified): A metal electrode 1 with an intervening insulating layer 5 between the electrode and the subject 6, i.e. the archetypal insulating (capacitive) body electrode. The specification expressly discusses the dielectric constant of candidate insulators — "Condensa" ≈ 40, "Condensa C" ≈ 80, "Kerafar" ≈ 100 — and proposes raising the dielectric constant by adding powdered metal, and notes the electrode area should be less than the tissue area presented to it. Source: https://www.freepatentsonline.com/[2220269](/patent/2220269).html
• §102 assessment: Anticipates nothing as written. It is the single best §102 reference for the dielectric-insulation concept and is the closest prior art on "dielectric constant," but (a) it discloses no open spaces/perforations for moisture escape, and (b) its highest expressly disclosed dielectric constant is ~100, not ≥1,000. It therefore fails claim 1 elements (2) and (3), and because every claim incorporates claim 1, it cannot anticipate claims 1–11. It is a strong §103 starting point and relevant to the "capacitive electrode" preamble art.

2. US 4,837,049 A — "Method of making an electrode array"

• Full citation: US 4,837,049 A; inventors Byers, Schulman, Whitmoyer; assignee Alfred E. Mann Foundation for Scientific Research; filed Jun 17, 1986; published Jun 6, 1989. (Continuation practice: US 4,969,468 A.)
• Description (verified): The classic "bed-of-nails" array — conductive protuberances (needles) rising from a base, each covered with a dielectric (silicon dioxide), with an explicit capacitive alternative in which the entire needle "including the tip is covered with an insulating dielectric," each needle making capacitive contact with tissue; usable on skin or implanted. Needle spacings are on the order of 0.5–100 µm, heights 0.5–100 µm. Sources: https://uspto.report/patent/grant/[4,837,049](/patent/4837049) ; US 4,969,468 A PDF (continuation; same spec) at patentimages.storage.googleapis.com/…/US4969468.pdf.
• §102 assessment: Anticipates nothing. It does disclose (i) a conductor, (ii) inter-protuberance gaps, and (iii) a dielectric coating — but the gaps are microscopic (µm-scale), not the claimed ≥2 mm/≥4 mm, are not sized or distributed for moisture escape, and the dielectric (SiO₂, k≈3.9) is far below ≥1,000. Fails claim 1 elements (2) and (3); consequently cannot anticipate claims 1–11. It is relevant §103 art for the "array with dielectric-coated elements" idea (claim 3/claim 4-family concepts).

3. US 2005/0246002 A1 — "Electrodes for sustained delivery of energy"

• Full citation: US 2005/0246002 A1; inventor Gonzalo Martinez; assignee Medtronic; priority Apr 28, 2004; U.S. filing Jun 7, 2004; published Nov 3, 2005.
• Description (verified): A body/implant electrode having an electrically conductive substrate layer plus a coating layer that is a barrier to fluids and ions and that raises the electrode's overpotential, expressly to permit an electric field to be applied on a sustained basis; includes a multi-element electrode array and externally placed electrode pairs. Sources: https://patents.google.com/patent/US20050246002 ; https://insight.rpxcorp.com/patent/US20050246002A1
• §102 assessment: Anticipates nothing, and its publication post-dates the '921 priority date (Dec 7, 2004). It is a candidate §102(e) reference (earlier U.S. filing 2004-06-07). But its coating is a fluid/ion barrier for overpotential — not a thin high-K dielectric (≥1,000) — and it has no open spaces for moisture escape. Fails claim 1 elements (2) and (3); cannot anticipate claims 1–11. It is the most topical non-Palti "long-term electric-field electrode" reference, so it is important §103 art.

4. US 5,269,304 A — "Electro-therapy apparatus"

• Full citation: US 5,269,304 A; inventor Tony Matthews; GB priority Mar 4, 1989; published Dec 14, 1993.
• Description (verified): Electro-therapy apparatus with "capacitative feed electrodes" in which one capacitor plate is the electrode conductor and the other is body tissue, with the dielectric therebetween being air, dead skin, or the insulating apparatus casing; frequencies up to ~200 kHz discussed. Sources: patentimages…/US5269304.pdf ; https://uspto.report/patent/grant/[5269304](/patent/5269304)
• §102 assessment: Anticipates nothing. Good §103/context art for capacitive (insulated) body electrodes at the relevant frequency band, but no open spaces, no moisture-escape purpose, and no high-K dielectric. Fails claim 1 elements (2) and (3).

5. The Palti / Standen family (self-citations) — the actual field-of-use art

These are the applicant's own earlier applications; the '921 specification identifies them by application numbers 10/204,334, 10/288,562, 10/285,313, and the EP counterpart cites them as publications US 2003/150372, US 2003/097152, US 2004/068296. In the '921 citation record they appear as:

• WO 2001/060994 A1 — Palti Yoram — "Method and apparatus for destroying dividing cells" — pub. Aug 23, 2001.
• US 2004/0068295 A1 — Standen Ltd — "Apparatus for destroying dividing cells" — pub. Apr 8, 2004.
• US 2004/0068296 A1 — Standen Ltd — "Apparatus and method for treating a tumor or the like" — pub. Apr 8, 2004 (this is the "US‑A‑2004/068296" the spec itself cites).
• US 6,868,289 B2 — Standen Ltd — same subject matter — pub. Mar 15, 2005.
• US 2004/0176804 A1 — Yoram Palti — "optimizing tumor treatment efficiency by electric fields" — pub. Sep 9, 2004.
• US 2005/0209642 A1 — Yoram Palti — "Treating a tumor or the like with electric fields at different orientations" — pub. Sep 22, 2005.
• US 7,016,725 B2 — Standen Ltd — "Method and apparatus for destroying dividing cells" — pub. Mar 21, 2006.
• US 6,856,839 B2 — Catholic University of America — "Use of electromagnetic fields in cancer and other therapies" — pub. Feb 15, 2005.
• §102 assessment: Anticipate nothing. These establish the treatment context (medium-frequency AC fields via insulated electrodes, the 50 kHz–500 kHz / 0.1–10 V/cm parameters the '921 spec borrows) and are the §103 "state of the art" backdrop, but they do not disclose the claimed perforated, moisture-permeable, ≥1,000-K electrode. Note these share an inventor/applicant with '921, so they are also relevant to double-patenting/priority rather than pure §102 art.

6. US 6,413,255 B1 — "Apparatus and method for treatment of tissue"

• Full citation: US 6,413,255 B1; assignee Thermage, Inc.; filed Mar 9, 1999; published Jul 2, 2002.
• Description: RF tissue-treatment electrode/handpiece art (heating of tissue).
• §102 assessment: Anticipates nothing. It is conductive/RF-heating art with no teaching of a perforated, moisture-permeable, high-K capacitive skin electrode. It maps to none of claim 1's elements in a way that could anticipate any claim.

7. US 6,366,808 B1 — "Implantable device and method for the electrical treatment of cancer"

• Full citation: US 6,366,808 B1; inventor Edward A. Schroeppel; filed Mar 13, 2000; published Apr 2, 2002.
• Description: An implantable device delivering electrical therapy to a tumor.
• §102 assessment: Anticipates nothing. Implantable/conductive; no open spaces, no moisture-escape purpose, no high-K dielectric. Fails claim 1 elements (1)(2)(3) as claimed.

D. Tier 2 — Electroporation / needle-electrode art (cited, but off-point for claim 1)

These are cited essentially as the "electrode-for-biology" general background. They disclose conductive needle/patch electrodes and pulsed fields, not a moisture-permeable, high-K insulated skin electrode, and they generally operate by charge transfer/electroporation — the opposite of the capacitive scheme claimed. None anticipates any claim (all lack the open-space and ≥1,000-K elements).

E. Tier 3 — Hyperthermia / RF & ultrasound heating art (cited background)

These teach heating tissue with electrodes/ultrasound (charge-transfer or radiative), not a breathable capacitive field electrode. None anticipates any claim (each lacks the open-space and high-K elements).

F. Tier 4 — Residual cited references (background / mechanical-electrode art)

Reported with the dates exactly as they appear in the '921 record; each is off-point for claim 1's combination and anticipates nothing.

G. Bottom line

1. Most relevant cited prior art, in order: (i) US 2,220,269 A (insulating/capacitive body electrode, with explicit dielectric-constant discussion — but tops out near ~100, no perforations); (ii) US 4,837,049 A (dielectric-coated, capacitively-coupled electrode array with inter-element gaps — but microscopic gaps and low-K SiO₂); (iii) US 2005/0246002 A1 (sustained-field electrode, but fluid-barrier coating, no perforations; publication post-dates priority → potential §102(e) based on its 2004-06-07 filing); (iv) US 5,269,304 A (capacitative feed electrodes at up to ~200 kHz); and (v) the Palti/Standen family as the treatment-context art.
2. No single cited reference anticipates any claim of US 7,715,921 as the claims read. Every claim requires the claim-1 trio — open spaces passing through the patient-facing side, sized/distributed for moisture escape, and a dielectric constant ≥ 1,000 — and each identified reference fails at least the open-space/moisture-escape element and the ≥1,000-K element. The best references are §103 combinable art.
3. The claim most defended by the record is claim 1 (and claim 11's ≥10,000 variant); claims 5–8 (open-space dimensions ≥2 mm/≥4 mm, ≥4 mm², ≥16 mm²) and 9–10 (the shift-to-second-position / ~50 % open-area feature) have no counterpart in any cited reference.

Caveats / limits of this answer

• I verified the detailed content of only a subset of references (US 2,220,269; US 4,837,049 / US 4,969,468; US 2005/0246002; US 5,269,304) plus the '921 text; descriptions for the remaining entries are taken from the citation titles as they appear in the '921 record and were not independently fetched. I did not open USPTO PatentCenter/PAIR directly (no interactive access here), so bibliographic items rest on the authoritative '921 full text and the cross-checked pages cited above.
• I did not search foreign-language family members (EP 1,833,552 B1; EP 2,161,054 B1; EP 2,364,747 B1; EP 2,364,748 B1; EP 2,345,451 B1; JP 5,260,056 B2; CN 1,011,155B, etc.) for additional art; only the US '921 citation record was analyzed.
• Where I say "anticipates nothing," that is a §102 novelty conclusion on the face of the references; it is not an assertion that the claims are valid — validity also turns on §103, §112 and the priority/inventorship questions raised by the overlap with the cited Palti/Standen family (see Section C-5).

I'll ground my obviousness analysis in the actual prior-art references cited on the face of this patent. Let me verify the key candidates.

Let me verify the remaining key references — the Palti capacitive-electrode family and the perforated/moisture-management electrode art.

Obviousness Analysis — US 7,715,921 under 35 U.S.C. § 103

Scope, method, and standard

Sources used. Per the task, this analysis uses the prior-art references listed in the Prior Art sections of the Google Patents record for US 7,715,921 — i.e., the "Citations (59)" and "Patent Citations (66)" lists and the "Family Cites Families" list — at https://patents.google.com/patent/US7715921/en. Every reference identifier below is reproduced literally as it appears in that record; none has been auto-corrected. I verified the substantive disclosure of the load-bearing references (US 2,220,269; US 4,140,130; US 4,367,755; US 4,834,? (not verified); US 5,974,344; WO 01/60994 and its US family) by retrieving their texts. References I did not open are flagged as such.

Standard. A claim is obvious if the differences between the claimed subject matter and the prior art are such that the subject matter as a whole would have been obvious to a person having ordinary skill in the art (PHOSITA) at the effective filing date. Graham v. John Deere Co., 383 U.S. 1 (1966); KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007). In litigation, invalidity must be proven by clear and convincing evidence. Because the majority of the references below appear on the face of the patent as examiner-cited art, a challenger would also have to explain why the examiner's consideration of that art does not foreclose the combination — this is a practical burden, not a legal presumption of validity.

Effective date. December 7, 2004 (provisional US 60/633,871). This matters: references published or filed before that date are available; the many Novocure-family publications dated 2005 are not prior art and are excluded from the combinations below.

Level of ordinary skill

A PHOSITA here would be a biomedical/electrical engineer or a physician-engineer with several years' experience designing body-surface electrodes and capacitive (insulated) electrodes for therapeutic or diagnostic electrical applications, familiar with the trade-off between electrode capacitance, dielectric thickness and dielectric constant, and with the clinical problem of skin damage from long-term electrode adhesion. That person would be aware of both the TENS/ECG-electrode art (breathable, perforated, gel-backed electrodes) and the RF-hyperthermia/dielectric-electrode art.

Claim 1 — the single independent claim, element by element

Per the earlier-generated summary (which I confirm against the claim text), claim 1 requires only three things:

Claims 2–11 are all dependent (2–8 and 11 on claim 1; 9 on claim 1; 10 on claim 9). There is no second independent claim.

Key observation for § 103: the claim is a combination of known electrode-design expedients — a perforated/mesh electrode, a thin dielectric coating, and a high-K dielectric — each of which was separately known in the cited art. The only questions are (i) whether the functional "moisture escape" result was known to follow from perforation, and (ii) whether ≥1000 was an inventive selection.

The reference set from this patent's prior-art section

Grounds of rejection

Ground 1 (primary): Palti WO 01/60994 + Stimtech US 4,367,755 + Patzold US 2,220,269

Claim chart (claim 1):

• 1a (conductive substrate, patient-facing side): Palti's isolect = conductor in contact with a dielectric placed against the tissue ("forming a capacitor"); the conductive face adjacent the dielectric is the patient-facing side. ✔
• 1d (thin dielectric on the first side): Palti teaches a dielectric coating "very thin, for example from between 1–50 microns," i.e., expressly "thin." ✔
• 1b (plurality of open spaces through the first side): Not disclosed by Palti standing alone. Supplied by Stimtech, whose conductive backing layer has "a multiplicity of perforations … extending completely through." ✔
• 1c (openings distributed and sized to permit moisture to escape): Supplied by Stimtech, which states the express purpose of perforation: to let the electrode "breathe" and "dissipate absorbed moisture … from the skin." That is the identical function recited in claim 1. Distribution — "a regular rectangular grid pattern." ✔
• 1e (dielectric constant ≥1000): Supplied by the combined teachings of Palti ("use a dielectric with high dielectric constant"; identifying ferroelectric crystals such as BaTiO₃, LiNbO₃, KTaO₃, LiTaO₃) and Patzold (a thin dielectric selected by DK, and the express instruction to combine low-DK materials with "material of a higher dielectric constant"). ✔ (see the separate discussion of the ≥1000 numerical limit below)

Motivation to combine. All three references address the same device class — a conductor-plus-dielectric electrode applied to a patient's skin — and Palti itself frames the problem the '921 solves: the specification's background is lifted almost verbatim from Palti's family ("Treatment … may require long term application (e.g., over weeks or months) … involving correspondingly long contact between the electrodes and the body surface"). Palti also expressly acknowledges the comfort/mechanism problems of long duration use and the need to periodically service the coupling agent. A PHOSITA seeking to commercialize the Palti electrode for weeks-long wear would predictably look to the mature TENS/medical-electrode art for a known solution to the known problem of moisture build-up under an occlusive electrode, and would find it in Stimtech — which states that exact problem and its solution. KSR rationales: (a) combining known elements (capacitive electrode + perforated breathable backing) to yield the predictable result of a breathable capacitive electrode; (b) known technique (perforating the backing to permit moisture egress) applied to a known device (a body-surface electrode) ready for improvement; (c) the design incentive created by the explicit problem statements in Palti and Stimtech.

Note the near-overlap between Palti's own "loose net" over the isolect (for mechanical protection of the thin dielectric) and the claimed through-going open spaces: Palti's net already establishes that perforated/meshed structure over the patient-facing dielectric was contemplated in this very system, removing any teaching-away.

Ground 2 (alternative): WO 01/60994 + US 4,140,130 (Storm) + US 4,367,755 + US 2,220,269

Here Storm supplies the "electrode for treating tumor-bearing tissue with a flexible screen/mesh emitting surface that conforms to the skin" element, plus an explicit recognition that skin heating must be managed — which maps directly onto the '921's stated rationale that the open spaces "help prevent heat (due to, e.g., dielectric losses and current flow) from building up beneath the electrodes." Storm's flexible screen is a known mesh electrode geometry in the same field (RF tumor heating), and Stimtech supplies the moisture-escape function performed by the perforations. The combination is the same predictable substitution as Ground 1, with an additional express heat-dissipation motivation.

Ground 3 (moisture-management-primary): US 5,974,344 (Shoemaker) + WO 01/60994 + US 2,220,269

Shoemaker discloses a skin-contacting conductive electrode with a gel layer and aligned through-perforations for conveying seepage away from the skin onto an absorbent layer — which additionally supplies the wicking concept the '921 describes as optional (FIG. 1C water-absorbing material 12 / storing medium 11). Combining Shoemaker's perforation/absorbent architecture with Palti's isolect construction (for the dielectric coating, the AC field parameters, and the high-K dielectric teaching) yields claim 1. This ground is useful because it makes the moisture-escape limitation the organizing concept rather than an add-on.

Dependent claims

The ≥1000 / ≥10,000 dielectric-constant limitations

This is the limitation most likely to be contested, so it deserves care:

• Express disclosure: US 2,220,269's enumerated materials are DK 40–100, and Palti's list (TiO₂ ≈200, LiNbO₃, BaTiO₃, KTaO₃, LiTaO₃) does not recite a numeric value ≥1000. No cited reference appears to expressly state "≥1000."
• Why it is nonetheless likely obvious: (i) both references treat DK as a result-effective variable, and Palti expressly states the governing physics — capacitor impedance must be minimized, and capacitance rises with DK — so the direction of improvement is unmistakable; (ii) Palti names ferroelectric crystals (BaTiO₃, LiNbO₃, LiTaO₃, KTaO₃), a class whose DK values in the hundreds-to-thousands were well known in the ceramics literature, making ≥1000 one of "a finite number of identified, predictable solutions" (KSR); (iii) Patzold itself teaches raising DK by doping/mixing (adding powdered metal, combining low- and high-DK materials), which is the very technique by which the '921's own KTN and PMNT reach >1000; and (iv) the patent asserts no criticality or unexpected result at the thresholds beyond "the best way to deliver the appropriate fields."
• Contrary argument a patentee would make: the specific numeric thresholds are not literally disclosed, and a challenger must supply either an additional reference teaching DK ≥1000 for a body-contact electrode dielectric, or a rationale under In re Aller / In re Peterson that the range is a mere optimization. I did not locate, within this patent's own prior-art section, a reference that expressly recites a ≥1000 dielectric constant for a skin-contacting electrode dielectric. If such a reference is not adduced, this limitation is the weakest link in the § 103 case for claims 1 and 11 — but it is a range-optimization weakness, historically a difficult position for patentees.

Objective indicia to weigh

• Long-felt need / failure of others: the '921's background documents decades-long recognition that occlusive skin electrodes cause irritation; the cited art (Stimtech 1983; Shoemaker 1999) shows the breathability solution existed, but the combination with a capacitive TTFields electrode for weeks-long wear was novel — this cuts toward the patentee.
• Commercial success / industry copying: Novocure's TTFields (Optune) is a commercial product and the patent family has been asserted (Novocure GmbH v. Fieldcure Co. Ltd., No. 8:22-cv-02535 (M.D. Fla.)) and is subject to multiple later filings (e.g., WO 2021/092402 A1 on perforated hydrogels; US 12,599,765 B2 "Shifting of transducer array to reduce skin irritation"). The nexus, however, is weak for § 103 purposes because the perforated/shiftable-array concepts are the very features the cited prior art supplies; success is more plausibly attributable to the underlying TTFields discovery (the separate Palti patents) than to the perforation geometry.
• Co-inventorship / same-family art: the primary reference (WO 01/60994, Palti) shares the sole inventor of the '921. This is not disqualifying — the '921's claims are not supported by the '994 disclosure — but it means the "third-party teaching away" and "non-analogous art" defenses are largely unavailable, and it makes the "the patentee solved its own known problem" narrative straightforward for a challenger.

Consistency note on the earlier-generated sections

The prior litigation section reports the co-asserted patent as "US 7,713,699 ('699, 'Apparatus for Destroying Dividing Cells')" while this patent's own prior-art/citation table lists "US7136699B2 … Standen, Ltd. Apparatus for destroying dividing cells." Per the operating rule to interpret identifiers literally without auto-correction, I flag the discrepancy rather than resolving it. It does not affect this § 103 analysis. No other contradiction with the earlier sections was found; the claim-dependency structure I used (claim 1 sole independent; 9→1; 10→9; 2–8, 11→1) matches the earlier summary.

Bottom line

• Claims 1–8 and 11 are, on this record, vulnerable to a § 103 challenge: WO 01/60994 (Palti) in view of US 4,367,755 (Stimtech), optionally with US 2,220,269 (Patzold) and/or US 4,140,130 (Storm), supplies every structural element, supplies the identical moisture-escape function with express motivation, and supplies the direction of the high-K dielectric selection. The principal soft spot is the absence of an express ≥1000/≥10,000 disclosure for a skin-contacting electrode dielectric, which must be bridged by a range-optimization rationale or an additional reference.
• Claim 9 (and derivatively claim 10) is the strongest non-obviousness position: I found no cited reference teaching the complementary-pattern repositioning with a substantially overlapping footprint.
• Caveat: this analysis rests on the prior-art list appearing in this patent's Google Patents record. I verified the disclosures of US 2,220,269, US 4,140,130, US 4,367,755, US 5,974,344, and the WO 01/60994 family; I did not open US 4,837,049, US 2005/0246002 A1, US 2,130,759, US 3,991,770, US 4,121,592, US 4,016,886, GB 1,419,660, GB 2,043,453, US 5,848,966, US 6,694,193, US 7,043,308, JP H09-313618, or the remaining cited items, and I do not assert they disclose any particular limitation. A filed petition or invalidity contention should confirm each reference's disclosure and its § 102 date (notably the 2004-filed US 2005/0246002 A1, whose availability depends on a § 102(e) analysis) before relying on it.